Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients
Mysa Saad, Internal Medicine Resident shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Our new study published in Thrombosis Research:
In ambulatory patients with cancer on apixaban thromboprophylaxis:
- Concurrent antiplatelet/NSAID use increases clinically relevant bleeding (HR 1.80)
- Antiplatelets were the main driver of increased bleeding risk (HR 2.02)
- NSAIDs did not have a significant impact on bleeding risk
- No significant reduction in VTE
These results highlight the need to carefully reassess indications for concurrent antiplatelet agents/NSAIDs when considering apixaban thromboprophylaxis in patients with cancer.”
Title: Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial
Authors: Mysa Saad, Tzu-Fei Wang, Ranjeeta Mallick, Danny Hill, Alejandro Lazo-Langner, Vicky Tagalakis, Philip S. Wells, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 16, 2026, 00:20Mettine Bos: Reflecting on a Fantastic ISTH 2026 in Paris with Team Leiden
-
Jul 16, 2026, 00:19Pierre Grès: Proud to Present My PhD Research at ISTH 2026
-
Jul 16, 2026, 00:19Francis Couturaud: Leela Breton Presents Promising PE Research at ISTH 2026
-
Jul 16, 2026, 00:18Alisa Wolberg: An Honor to Present the Gualtiero Palareti Memorial Plenary Lecture at ISTH 2026
-
Jul 16, 2026, 00:17Edward Lee Carter: What ISTH 2026 Tells Us About the Next Era of Thrombosis Care
-
Jul 16, 2026, 00:17Marc Carrier: Celebrating 25 Years of the Adult Thrombosis Fellowship Program at ISTH 2026
-
Jul 16, 2026, 00:16Nikolaos Kotsiou: The Privilege of Presenting Our Clinic’s Newest Findings at My 1st ISTH 2026
-
Jul 16, 2026, 00:14Empowering the Next Generation of Bleeding Disorders Leaders – WFH
-
Jul 16, 2026, 00:13Wolfgang Miesbach: VOYAGER1 Highlights the Potential of Oral Inno8 at ISTH 2026